Articolul precedent |
Articolul urmator |
300 7 |
Ultima descărcare din IBN: 2022-10-04 11:34 |
SM ISO690:2012 ZAMISNII, Galina. Contemporary diagnosis of oncoviruses. In: MedEspera: International Medical Congress for Students and Young Doctors, Ed. 7th edition, 3-5 mai 2018, Chişinău. Chisinau, Republic of Moldova: 2018, 7, pp. 196-197. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
MedEspera 7, 2018 |
|||||
Congresul "International Medical Congress for Students and Young Doctors" 7th edition, Chişinău, Moldova, 3-5 mai 2018 | |||||
|
|||||
Pag. 196-197 | |||||
|
|||||
Descarcă PDF | |||||
Rezumat | |||||
Introduction. The topic of this paper is the contemporary diagnosis of the oncoviruses. The key concepts we have worked with are the following: malignant transformations, skin tumors, DNA genome, Epstein-Barr virus, B or C hepatitis virus, human papilloma virus, cervical cancer, Papanicola test and HPV test. Aim of the study. Identification and analysis of infectious origin of oncoviruses, contemporary diagnosis of oncoviruses, and especially HPV has been investigated. This review summarizes the molecular testing methods currently used for the detection and genotyping of HPV DNA and discusses future potential approaches. Materials and methods. Investigational protocol included: General Blood Test and Biochemical test, Antigen Antibody Test for Epstein-Barr Virus, Abdominal Ecography, CT with Contrast Substances, MRI, Babes Papanicolau Test, HPV Test, Colposcopy, Cervical Biopsy. Results. The results of the study indicate a modern approach with the inclusion of a new research vision in the field of oncoviruses and the determination of a correct diagnosis. Conclusions. Finally, in our opinion, much more information is needed on the prevalence of globally high-risk oncogenic serotypes, information needed both to implement a screening program that includes diagnostic tests for the most prevalent serotypes, as well as for theestablishment of a vaccination program. Further research is also needed to generate data on long-term clinical effectiveness and duration of protection, following 2 and 3-dose regimens. |
|||||
Cuvinte-cheie Diagnosis, HPV, oncovirus, Colposcopy, oncogene |
|||||
|
Dublin Core Export
<?xml version='1.0' encoding='utf-8'?> <oai_dc:dc xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:oai_dc='http://www.openarchives.org/OAI/2.0/oai_dc/' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd'> <dc:creator>Zamisnii, G.</dc:creator> <dc:date>2018</dc:date> <dc:description xml:lang='en'><p>Introduction. The topic of this paper is the contemporary diagnosis of the oncoviruses. The key concepts we have worked with are the following: malignant transformations, skin tumors, DNA genome, Epstein-Barr virus, B or C hepatitis virus, human papilloma virus, cervical cancer, Papanicola test and HPV test. Aim of the study. Identification and analysis of infectious origin of oncoviruses, contemporary diagnosis of oncoviruses, and especially HPV has been investigated. This review summarizes the molecular testing methods currently used for the detection and genotyping of HPV DNA and discusses future potential approaches. Materials and methods. Investigational protocol included: General Blood Test and Biochemical test, Antigen Antibody Test for Epstein-Barr Virus, Abdominal Ecography, CT with Contrast Substances, MRI, Babes Papanicolau Test, HPV Test, Colposcopy, Cervical Biopsy. Results. The results of the study indicate a modern approach with the inclusion of a new research vision in the field of oncoviruses and the determination of a correct diagnosis. Conclusions. Finally, in our opinion, much more information is needed on the prevalence of globally high-risk oncogenic serotypes, information needed both to implement a screening program that includes diagnostic tests for the most prevalent serotypes, as well as for theestablishment of a vaccination program. Further research is also needed to generate data on long-term clinical effectiveness and duration of protection, following 2 and 3-dose regimens.</p></dc:description> <dc:source>MedEspera (7) 196-197</dc:source> <dc:subject>Diagnosis</dc:subject> <dc:subject>HPV</dc:subject> <dc:subject>oncovirus</dc:subject> <dc:subject>Colposcopy</dc:subject> <dc:subject>oncogene</dc:subject> <dc:title>Contemporary diagnosis of oncoviruses</dc:title> <dc:type>info:eu-repo/semantics/article</dc:type> </oai_dc:dc>